title: [The characteristics of epidemic influenza A and B virus strains circulating in Russia during the 2007-2008 season].
abstract: In 2007-2008 in Russia, the epidemic upsurge of influenza morbidity was caused by the active circulation of influenza A(H1N1, A(H3N2), and B viruses. The center for Ecology and Epidemiology of Influenza studied 334 epidemic strains. The results of a comparative study of the svirus specificity of commercial test systems (AmpliSens Influenza virus A/B and AmpliSens Influenza virus A/H5N1) for the polymerase chain reaction diagnosis and virological assays, including virus isolation, revealed their high correlation, which confirms that they may be expensively used to monitor the circulation of influenza viruses in the Russian Federation. All the strains were isolated in the MDCK cell culture. Influenza A(H1N1) viruses (n = 127) were antigenic variants of the reference strains A/Solomon Islands/3/06 and A/Brisbane/59107. Influenza A(H3N2) viruses (n = 49) were antigenic variants of the reference strains A/Wisconsin/67/05 and A/Brisbane/10/08. One hundred and fifty seven Influenza B strains were drift variants of the reference strains B/Florida/4/06 and B/Shanghai/361/02 of lineage B/Yamagata/16/88 and one strain, a variant of Malaysia/2506/04 related to lineage B/victoria/2/87. The isolates interacted actively with human 0(I) blood group erythrocytes and much more weakly with chicken ones. All study influenza A(H1N1) viruses (n = 74) preserved their sensitivity to rimantadine while 24 (77%) of the 31 study influenza A(H3N2) virus strains were resistant. A study of the time course of changes in the generation of antibodies in the donor sera obtained in Moscow and the Moscow Region in different periods of the epidemic process revealed an increase in antibodies to the reference influenza A and B virus strains circulating in this period.
authors.forename: V T
authors.initials: VT
authors.lastname: Ivanova
authors.forename: S V
authors.initials: SV
authors.lastname: Trushakova
authors.forename: T A
authors.initials: TA
authors.lastname: Oskerko
authors.forename: E S
authors.initials: ES
authors.lastname: Shevchenko
authors.forename: L V
authors.initials: LV
authors.lastname: Kolobukhina
authors.forename: R V
authors.initials: RV
authors.lastname: Vartanian
authors.forename: N V
authors.initials: NV
authors.lastname: Beliakova
authors.forename: S B
authors.initials: SB
authors.lastname: Iatsyshina
authors.forename: E L
authors.initials: EL
authors.lastname: Feodoritova
authors.forename: N D
authors.initials: ND
authors.lastname: Zueva
authors.forename: E I
authors.initials: EI
authors.lastname: Burtseva
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000940:Antigenic Variation; D000956:Antigens, Viral / Q000235:genetics; D000998:Antiviral Agents / Q000494:pharmacology; D024882:Drug Resistance, Viral; D004912:Erythrocytes / Q000276:immunology; D006387:Hemagglutination, Viral; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000145:classification* / Q000187:drug effects / Q000502:physiology; D053122:Influenza A Virus, H3N2 Subtype / Q000145:classification* / Q000187:drug effects / Q000502:physiology; D007251:Influenza, Human / Q000097:blood / Q000453:epidemiology* / Q000821:virology; D008826:Microbial Sensitivity Tests; D012299:Rimantadine / Q000494:pharmacology; D012426:Russia / Q000453:epidemiology; D012621:Seasons
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D000998:Antiviral Agents; D012299:Rimantadine